Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun;14(3):145-153.
doi: 10.1007/s11899-019-00508-w.

Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms

Laura F Mendez Luque  1 , Amanda L Blackmon  2 , Gajalakshmi Ramanathan  2 , Angela G Fleischman  3   4   5
Affiliations
Review

Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms

Laura F Mendez Luque et al. Curr Hematol Malig Rep. 2019 Jun.

Abstract

Purpose of review: Chronic inflammation is a characteristic feature of myeloproliferative neoplasm (MPN) and impacts many aspects of the disease including initiation, progression, and symptomatology.

Recent findings: The chronic inflammatory state of MPN results from disruption of immune signaling pathways leading to overproduction of inflammatory cytokines by both the neoplastic clones and bystander immune cells. This chronic inflammation may allow for the neoplastic clone to gain a selective advantage. The symptomatic burden felt by MPN patients may be a result of the chronic inflammation associated with MPN, as several cytokines have been linked with different symptoms. Pharmacologic as well as nonpharmacologic treatments of the inflammatory component of this disease may lead to decreased symptomatic burden, prevention of disease progression, and improvement in overall disease trajectory. Inflammation plays a key role in the pathogenesis of MPN and represents an important therapeutic target.

Keywords: Diet in cancer; Fatigue; Inflammation in cancer; Inflammatory cytokines; JAK/STAT signaling; Lifestyle in cancer; Myeloproliferative neoplasm; Nonpharmacological approaches; Quality of life.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Factors Influencing Inflammation in Myeloproliferative Neoplasms.
Chronic inflammation is a multifactorial process in MPN. It is difficult to assess if it is the result from a preceding pro inflammatory environment or if the neoplastic clone itself predisposes to its development. Understanding the different drivers of inflammation in MPN may lead to targeted treatments in the future.
Figure 2.
Figure 2.. Nonpharmacologic Approaches to Reduce Inflammation in MPN.
Maintaining a healthy lifestyle may help prevent a chronic inflammatory environment in patients with strong family history of MPN and/or patients on early stages of the disease. These nonpharmacologic approaches may be able to reduce overall inflammation with the goal of reversing some of these factors or mitigating their effects.
See this image and copyright information in PMC

References

    1. Hoermann G, Greiner G, Valent P. Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms. Mediators of inflammation. 2015;2015:869242. - PMC - PubMed
    1. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(10):1356–63. - PubMed
    1. Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood. 2010;115(25):5232–40. - PMC - PubMed
    1. Hasselbalch HC. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leukemia research. 2012. - PubMed
    1. Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, et al. TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood. 2011;118(24):6392–8. - PMC - PubMed

    2. This study demonstrates that JAK2 mutant hematopoietic progenitors are resistant to inflammation and that this may allow for the emergence of JAK2 mutant cells in the context of chronic inflammation.